Technical Analysis for JNCE - Jounce Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 6.6 -3.93% -0.27
JNCE closed down 3.93 percent on Monday, March 18, 2019, on 1.86 times normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical JNCE trend table...

Date Alert Name Type % Chg
Mar 18 Calm After Storm Range Contraction 0.00%
Mar 18 Upper Bollinger Band Walk Strength 0.00%
Mar 18 Outside Day Range Expansion 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Overbought Stochastic Strength 0.00%
Mar 15 180 Bullish Setup Bullish Swing Setup -3.93%
Mar 15 Calm After Storm Range Contraction -3.93%
Mar 15 NR7 Range Contraction -3.93%
Mar 15 Upper Bollinger Band Walk Strength -3.93%
Mar 15 Inside Day Range Contraction -3.93%

Older signals for JNCE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
Biotechnology Life Sciences Biology Natural Sciences Immunology Solid Tumors Immunotherapy Immune System Monoclonal Antibodies
Is JNCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 12 Investors Who Bought Jounce Therapeutics (NASDAQ:JNCE) Shares A Year Ago Are Now Down 80%
Mar 12 Microcaps mostly among midday movers
Mar 12 Seelos Therapeutics and Bio-Path Holdings among healthcare gainers; NuVasive and Zafgen among the losers
Mar 11 Jounce Therapeutics (JNCE) Investor Presentation - Slideshow
Mar 8 Edited Transcript of JNCE.O earnings conference call or presentation 6-Mar-19 1:00pm GMT
Mar 6 Jounce Therapeutics (JNCE) CEO Rich Murray on Q4 2018 Results - Earnings Call Transcript
Mar 6 The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split
Mar 6 Jounce Therapeutics Q4 top line up 55%
Mar 6 Jounce Therapeutics beats by $0.30, beats on revenue
Mar 6 Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
See more JNCE news...
Indicators
Indicator Value
52 Week High 27.24
52 Week Low 2.66
Average Volume 249,429
200-Day Moving Average 5.8952
50-Day Moving Average 4.6104
20-Day Moving Average 5.1205
10-Day Moving Average 5.864
Average True Range 0.5521
ADX 36.12
+DI 31.3406
-DI 10.5965
Chandelier Exit (Long, 3 ATRs ) 5.6937
Chandelier Exit (Short, 3 ATRs ) 5.6763
Upper Bollinger Band 7.0907
Lower Bollinger Band 3.1503
Percent B (%b) 0.88
BandWidth 76.953423
MACD Line 0.645
MACD Signal Line 0.432
MACD Histogram 0.213
Fundamentals Value
Market Cap 212.22 Million
Num Shares 32.2 Million
EPS 0.03
Price-to-Earnings (P/E) Ratio 220.00
Price-to-Sales 5.66
Price-to-Book 2.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.04
Resistance 3 (R3) 8.04 7.56 7.80
Resistance 2 (R2) 7.56 7.19 7.56 7.72
Resistance 1 (R1) 7.08 6.97 6.84 7.08 7.64
Pivot Point 6.60 6.60 6.48 6.60 6.60
Support 1 (S1) 6.12 6.23 5.88 6.12 5.56
Support 2 (S2) 5.64 6.01 5.64 5.48
Support 3 (S3) 5.16 5.64 5.40
Support 4 (S4) 5.16